Quantcast
Last updated on April 24, 2014 at 11:50 EDT

SenoRx Announces Claim Construction Hearing Held in Pending Hologic V. SenoRx Litigation

October 16, 2008

ALISO VIEJO, Calif., Oct. 16, 2008 (GLOBE NEWSWIRE) — SenoRx (Nasdaq:SENO) today announced that a Markman claim construction hearing was held on October 15, 2008 by the United States District Court for the Northern District of California in the currently pending patent litigation between Hologic and SenoRx. No ruling has yet been issued.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distributors in more than 20 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.

The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  SenoRx, Inc.           Lila Churney, Director of Investor Relations           949-362-4800 x132